|
 The
latest figures from the 1st Half of 2012, Helmut Kraft shared
with charge from the Chief Financial Officer.
The research and development costs were in the first six months
of the current fiscal year to 25.7 million euros (2011: 23.5
million euros). Due to the business model operates Stada AG no
research for new pharmaceutical agents, it is only to
development costs. The Group also capitalized in the first half
of 2012, expenses for new products in the amount of EUR 6.9
million (2011: EUR 5.4 million).
The core segment of Stada AG, generics had, in the first half of
2012, sales increased by 2 percent to 585.1 million euros (2011:
572.1 million euros). So had generics in the period accounted
for 66.1 per cent (2011: 69.0 percent). Group sales Adjusted,
generics sales rose 1 percent in the group.
Brand products increased in the current fiscal year, sales
increased by 23 percent to 284.5 million euros (2011: 231
million euros). So branded wear in the period with 32.1 percent
(2011: 27.8 percent) of total Group sales. Adjusted sales of
branded products placed in the Group by 6 percent.
The equity ratio as at 30th June 2012 is 29.7 per cent (31
December 2011: 30.9 percent) lag so in a reasonable range in
light of the first half of 2012 very high payments for the
acquisition of companies and products in the amount of 377.5
million euros (2011: 51.5 million euros) 30 Net debt as June
2012 rose to 1,279.1 million euros (31 December 2011: 900.3
million euros).
The free cash flow in the first half of the current fiscal year
was EUR -356.4 million (2011: -2.4 million euros). This resulted
due to high payments for investments in investing activities of
the Group.
Against the background of the difficult market conditions in
Western Europe, the increase in adjusted EBITDA margin in the
first half compared to the same period appears encouraging.
Synergies from the running cost efficiency program "STADA -
build the future" and growth in Russia have offset the price
pressure from Western Europe. Performance of the brand means
that the Group is independent against government price
regulation, explained Kraft.
With a view to continuing decline of the product chain Stada AG
Board expects to continue with a continuous flow of new generic
products in the EU countries.
See also
Stada AG in Bad Vilbel sells two Russian
factories
|
